Heidi Shea, MD
Endocrinology, Diabetes & Metabolism · Plano, TXNPI 1578517926
Payments from drug & device makers
Across 1,449 payments — averaging $859.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$365K
- Rhythm Pharmaceuticals, Inc.$275K
- Novartis$174K
- Dexcom, Inc.$109K
- Novo Nordisk$83K
- Soleno Therapeutics, Inc.$48K
- plus $192K from 54 others
Across 2 payments — averaging $27,887 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$56K
What the payments were for
- Consulting fees$46,56825%
- Speaking & faculty fees$108,14058%
- Travel & lodging$8,9855%
- Food & beverage$22,05112%
- Education$2870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$45,422
- Sogroya$26,896
- SKYTROFA$21,155
- Imcivree$17,784
- CRENESSITY$13,893
- VYKAT XR$7,500
- SUPPRELIN$6,210
- Macrilen$5,100
- t:slim X2 insulin pump$2,200
- t-slim insulin pump$1,100
- Omnipod$154
- Repatha$122
- BEYFORTUS$120
- TWIIST$111
- INPEN SMART INSULIN DELIVERY SYSTEM$111
- Ozempic$105
How this compares
$1,245,452 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $51,333 |
| TrulicityDulaglutide | 32 | $48,394 |
| MounjaroTirzepatide | 34 | $41,462 |
| JardianceEmpagliflozin | 27 | $41,415 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $22,057 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $8,527 |
| SynthroidLevothyroxine Sodium | 86 | $8,509 |
| Testosterone | 13 | $2,799 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $2,159 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 13 | $2,138 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $1,931 |
| Levothyroxine Sodium | 207 | $1,835 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,783 |
| Liothyronine Sodium | 34 | $1,457 |
| Potassium Chloride | 11 | $739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,093 | $89,85666 claims |
| Novo NordiskOzempic | $83,210 | $51,33339 claims |
| Boehringer IngelheimJardiance | $38,331 | $41,41527 claims |
| AbbVieSynthroid | $21,927 | $8,50986 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $452 | $1,835207 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Plano
- Rosemarie LajaraPlano$1.2M
- Mitchell SorsbyPlano$945K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.